| Phase 2/3 |
| NCT03081143 |
Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or… |
Advanced Gastric or EGJ Cancer |
Active, Not Recruiting |
| Phase 2 |
| NCT07176312 |
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive… |
Gastroesophageal Adenocarcinoma |
Recruiting |
| NCT04522544 |
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC |
Hepatocellular Carcinoma Non-resectable |
Recruiting |
| NCT06981325 |
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced… |
Basal Cell Carcinoma (BCC) |
Recruiting |
| NCT07110038 |
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab… |
Penile Squamous Cell Carcinoma (PSCC) |
Recruiting |
| NCT07260175 |
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in… |
Cholangiocarcinoma |
Recruiting |
| NCT06680622 |
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the… |
Metastatic Gastro-esophageal Adenocarcinoma |
Active, Not Recruiting |
| NCT04318938 |
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping |
NSCLC |
Active, Not Recruiting |
| NCT06178445 |
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated… |
Biliary Tract Cancer |
Active, Not Recruiting |
| NCT07507968 |
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal… |
Esophagogastric Adenocarcinoma |
Not Yet Recruiting |
| NCT05798156 |
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With… |
Lymphoma, Large B-Cell, Diffuse |
Active, Not Recruiting |
| NCT07387198 |
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab |
Merkel Cell Carcinoma, Stage I |
Not Yet Recruiting |
| NCT07542678 |
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell… |
Relapsed /Refractory DLBCL |
Not Yet Recruiting |
| Phase 1/2 |
| NCT06731803 |
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing… |
Esophagogastric Adenocarcinoma |
Active, Not Recruiting |
| Phase 1 |
| NCT03252938 |
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors |
Solid Tumors |
Active, Not Recruiting |
| Not specified |
| NCT04122872 |
GISAR German Interdisciplinary Sarcoma Registry |
Sarcoma |
Recruiting |
| NCT07365930 |
NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy |
Hepatocellular Carcinoma (HCC) |
Recruiting |
| NCT07510724 |
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint… |
Small Cell Lung Cancer (SCLC) |
Recruiting |